| |
Before propensity score matching
|
After propensity score matching(1:1)
|
|---|
| |
BTS (n = 49)
|
ES (n = 118)
|
P
|
BTS (n = 49)
|
ES (n = 49)
|
P
|
|---|
|
Sex
| | |
0.152
| | |
0.817
|
|
Male
|
36 (73.5 %)
|
73 (61.9 %)
| |
36 (73.5 %)
|
37 (75.5 %)
| |
|
Female
|
13 (26.5 %)
|
45 (38.1 %)
| |
13 (26.5 %)
|
12 (24.5 %)
| |
|
Age(mean(SD),y)
|
68.8 (11.1)
|
68.3 (12.6)
|
0.811
|
68.8 (11.1)
|
68.8 (13.8)
|
0.872
|
|
Age range (y)
| | |
0.843
| | |
0.757
|
|
25–59
|
10 (20.4 %)
|
26 (22.0 %)
| |
10 (20.4 %)
|
13 (26.5 %)
| |
|
60–69
|
18 (36.7 %)
|
36 (30.5 %)
| |
18 (36.7 %)
|
15 (30.6 %)
| |
|
70–79
|
10 (20.4 %)
|
29 (24.6 %)
| |
10 (20.4 %)
|
10 (20.4 %)
| |
|
80–95
|
11 (22.4 %)
|
27 (22.9 %)
| |
11 (22.4 %)
|
11 (22.4 %)
| |
|
ASA score
| | |
0.348
| | |
0.399
|
|
I
|
6 (12.2 %)
|
28 (23.7 %)
| |
6 (12.2 %)
|
13 (26.5 %)
| |
|
II
|
23 (46.9 %)
|
48 (40.7 %)
| |
23 (46.9 %)
|
16 (32.7 %)
| |
|
III
|
17 (34.7 %)
|
40 (33.9 %)
| |
17 (34.7 %)
|
18 (36.7 %)
| |
|
IV
|
3 (6.1 %)
|
2 (1.7 %)
| |
3 (6.1 %)
|
2 (4.1 %)
| |
|
Comorbidities
| | | | | | |
|
CAD
|
9 (18.4 %)
|
10 (8.5 %)
|
0.007
|
9 (18.4 %)
|
6 (12.2 %)
|
0.400
|
|
Hypertension
|
18 (36.7 %)
|
43 (36.4 %)
|
0.133
|
18 (36.7 %)
|
17 (34.7 %)
|
0.833
|
|
Diabetes
|
3 (6.1 %)
|
18 (15.3 %)
|
0.333
|
3 (6.1 %)
|
5 (10.2 %)
|
0.461
|
|
CPD
|
4 (8.2 %)
|
6 (5.1 %)
|
0.181
|
4 (8.2 %)
|
4 (8.2 %)
|
1.000
|
|
Renal dysfunction
|
2 (4.1 %)
|
5 (4.2 %)
|
0.705
|
2 (4.1 %)
|
3 (6.1 %)
|
0.646
|
|
Biliary diseases
|
6 (12.2 %)
|
14 (11.9 %)
|
0.412
|
6 (12.2 %)
|
5 (10.2 %)
|
0.749
|
|
CVD
|
2 (4.1 %)
|
6 (5.1 %)
|
0.873
|
2 (4.1 %)
|
3 (6.1 %)
|
0.646
|
|
Tumor location
| | |
0.086
| | |
0.243
|
|
Splenic flexure
|
8 (16.3 %)
|
10 (8.5 %)
| |
8 (16.3 %)
|
5 (10.2 %)
| |
|
Descending colon
|
6 (12.2 %)
|
30 (25.4 %)
| |
6 (12.2 %)
|
12 (24.5 %)
| |
|
Sigmoid colon
|
35 (71.4 %)
|
78 (66.1 %)
| |
35 (71.4 %)
|
32 (65.3 %)
| |
|
cTNM stage
| | |
0.630
| | |
0.560
|
|
I–III
|
47 (95.9 %)
|
111 (94.1 %)
| |
47 (95.9 %)
|
48 (98.0 %)
| |
|
IV
|
2 (4.1 %)
|
7 (5.9 %)
| |
2 (4.1 %)
|
1 (2.0 %)
| |
- CAD coronary artery disease, CPD chronic pulmonary disease, CVD cerebrovascular disease
- Data are presented as the number (percentage) of patients unless otherwise indicated
